Hainan Huigu Pharmaceutical Co., Ltd

Primary Objective: To conduct a bioequivalence study of single-dose oral administration of guanfacine hydrochloride extended-release tablets (test formulation T, manufactured by Hainan Huigu Pharmaceutical Co., Ltd., strength: 2 mg/tablet) and guanfacine hydrochloride extended-release tablets (reference formulation R, licensed by Takeda Pharmaceuticals America, Inc., manufactured by Patheon Manufacturing Services LLC, trade name: Intuniv®, strength: 2 mg/tablet) in healthy participants under fasting/postprandial conditions. The aim was to investigate the absorption rate and extent of absorption of the test and reference formulations in humans, and to evaluate their bioequivalence. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants in China.